Results: For the entire group median follow-up and overall survival (OS) were: 17.7 months (mo) (IQR: 10.3-27.9) and 19.1 mo (95% CI 13.9-24.3). Median tBED for entire group was 45.8 Gy tBED in SD and ED group were 42.2 (IQR 37.4-45.2) and 48.9 Gy (IQR 45.7-49.7) Univariate analysis by groups: Actuarial median OS: SD vs. ED was: 17 mo (95% CI 13.6-20.3) vs. 22.3 mo (95% CI 9.6-35) p = 0.18. Actuarial median DFS SD vs. ED was: 8.3 (95% IC 7.2 -9.3) vs. 12.8 mo (95% IC 3 -22.7) p = 0.009. Actuarial median TPFS (mo) SD vs. ED was: 8.4 (95% CI 7.2-9.5) vs. 21.8 (95% CI 13.2-30.5) p = 0.003. On multivariate analysis significant predictors for OS, DFS and TPFS are depicted on table: radiotherapy dose was found not to be a significant factor.
Purpose or Objective: Radiotherapy with or without chemotherapy is commonly used for isolated loco-regional recurrence of non-small cell lung cancer (NSCLC) after initial surgery. This study was undertaken to evaluate the outcomes and complications of curative radiotherapy for locoregionally recurrent NSCLC.
Material and Methods:
Medical records of 57 patients who received curative radiotherapy for locoregionally recurrent NSCLC without distant metastasis after surgery from 2004 to 2014 were retrospectively reviewed. At the time of recurrence, the median age was 67 years (range 34-81 years), and most patients (84.2%) have good ECOG performance status. All patients initially received a curative intent operation, and the median disease-free interval was 14 months. For locoregionally recurrent lung cancer, forty-two patients were treated with concurrent chemoradiotherapy (CCRT), and 15 patients with radiotherapy alone. Radiation dose ranged from 45 Gy to 70 Gy (median 66 Gy) by a threedimensional conformal technique. Lung function change after radiotherapy was evaluated by comparing pulmonary function tests before and after radiotherapy.
Results:
Median follow-up after recurrence was 20 months. Six patients showed a complete response, and 39 patients showed a partial response. The median survival was 30 months. Two-year locoregional recurrence-free survival (LRFS), distant metastasis-free survival (DMFS), disease-free survival (DFS) and overall survival (OS) rate were 46.1%, 37.2%, 31.9%, and 65.1%, respectively. Eleven patients showed disease progression within the radiation field after radiotherapy. Pulmonary function decreased meaningfully after radiotherapy, and radiation pneumonitis of any grade was seen in 19 patients. In the multivariate analysis, age under 70 years was associated with good OS (p= 0.047); concurrent chemoradiotherapy with good OS (p= 0.014), and DFS (p= 0.003); and single-station recurrence with good OS (p=0.01), DFS (p=0.022), and LRFS (p=0.01).
Conclusion:
Patients who have locoregionally recurrent NSCLC showed favorable survival outcomes with salvage radiotherapy. However, lung function should be carefully evaluated before and after radiotherapy. Young age, single site recurrence, and the use of CCRT were good prognostic factors of overall survival. In patients with good prognostic factors and suitable for curative radiotherapy, CCRT could be considered to improve treatment outcomes. Purpose or Objective: Precise delineation of primary lung cancer mass and involved mediastinal LN is very important requirement in order to improve radiotherapy outcome and minimize treatment toxicity. Diffusion weighted MRI (DW-MRI) is a recently introduced functional imaging modality, having higher sensitivity and specificity than CT to differentiate lung cancer from post-obstructive lobar collapse . And also able to pinpoint lymph nodes with and without metastasis. The apparent diffusion coefficient (ADC) is the quantitative parameter of DW-MRI with cut off value 1.4 x 103 mm2/s which can be used as a good tool to contour Target volumes in lung cancer. the aim is to study the feasibility of using the images of DW-MRI and data of ADC map for radiotherapy contouring purposes Material and Methods: Twenty cases of newly diagnosed lung cancer patients underwent CT chest with contrast and respiratory gatted DW-MRI with b value of 0, 500, 1000s/mms . Both studies were obtained in the same position, respiratory phase and slice thickness (5mm) in order to allow proper image fusion. For each patient, we've delineated GTV for primary lung mass and GTV-LN for involved mediastinal LN on both CT scan (guided by size) and DW-MRI (guided by T2W and the ADC map ) together with delineation of the nearby risk structures. Auto margins were taken for the CTV and the PTV. The impact of using MRI on stage and different treated volumes was assessed and compared.
EP-1219

Results:
The main result was the reduction in primary and nodal volumes due to better definition of lung mass and nearby lung Collapse , the latter could be easily defined in 14 cases on the DW-MRI vs. 7 cases only by CT scans (P=0.016). Median GTV total (sum of 1ry and nodal GTV), on MRI Diffusion compared to that on the CT scan was 354 and 386 cm3 respectively (P= 0.009). In 15 cases, a mean decrease in the GTV total of 34% ±56% (median, 9%; range, 0.2-32.5%) by using DW-MRI. only in three other cases a mean increase in the GTV total of 12.7% ±14.9% (median, 9.7%; range, 0.4-221%). was found. The median PTVs on the CT scans vs. the MRI Diffusion were 1623 (range, 493-2965 cm3) & 1419 (range, 542-3158 cm3) respectively which was statistically non significant (P= 0.391).
Conclusion:
This pilot prospective study concluded that DW-MRI as a functional image can aid in proper definition and delineation of the target volumes after fusion of DWI and the CT images . GTV Total decreased in most cases due to exclusion of collapse, consolidation, reactionary and inflammatory LN, however GTV total was increased in 3/20 patients due to better nodal detection and better visualization of borders adjacent to the mediastinum and chest wall. DW MRI could be a future good tool for proper staging and guidance of radiotherapy in NSCLC cases indicated for chemo/radiation. Purpose or Objective: Purpose: The aim of this work was to compare the patterns of NSCLC relapses after combined modality therapy with postoperative hypofractionated and conventionally fractionated radiotherapy and after sugery Material and Methods: Material/methods. We treated 528 patients between January 1990 and January 2014 (men -445, women -83) aged 27-78 years (median age 59) with morphologically proven NSCLC (adenocarcinoma -161, squamous cell cancer-289, other types -70 patients); stage I-126, stage II -117, III -111. All patients were operated: pnevmonectomy -180, lobe/belobectomy -304, segmentectomy -30, wedge resection -11. 227 patients received neoadjuvant or adjuvant platinum-based chemotherapy. Three groups were retrospectively analyzed: group I -174 patients without postoperative radiotherapy (PORT), group II -180 patients with postoperative hypofractionated radiotherapy with daily dose 3Gy up to the total dose 36Gy-39Gy (EQD2= 43-47Gy, α/β=3) and group III -174 patients with postoperative radiotherapy with daily dose 2Gy up to the total dose 44Gy. Bronchial stump, involved regional lymphatic nodes and uninvolved groups (2R, 2L, 3a, 3p, 4R, 4L, 5, 6, 7 according to IASLC classification) were included in the CTV. The groups were comparable in the following parameters: age, ECOG status, stage, T-and N -classification and the proportion of the patients treated with chemotherapy. The duration of the follow-up was 0,33-16,0 years, median -2,25 years. The relapses were classified as local (in bronchial stump), regional, or distant. In the cases of mixt relapses (local ± regional ±distant) they were included in each category.
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Results:
Results. 263(49,8%) patients relapsed: 231 (43,8%) had distant metastases, local relapse -51 (9,7%), regional relapse -54 (10,2%). The pattern of the relapses in each group is presented in the table.
Conclusion:
Conclusion. Hypofractionated postoperative radiotherapy (daily dose 3Gy, total dose 36-39Gy) significantly decrease the probability of local and regional relapse in NSCLC patients as well as the total number of the relapses without any effect with regard to distant metastases. Hypofractionated PORT is equally effective as conventional PORT (daily dose 2Gy, total dose 44Gy) with regard to locoregional control but has the clear logistical advantage.
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